Last updated: February 20, 2026
What is the Scope of Patent EP3351249?
Patent EP3351249 pertains to a pharmaceutical compound or formulation with specific therapeutic applications. The scope covers the exact chemical entities, compositions, administration methods, and potential uses described in the claims, aimed at protecting innovative treatment methods or drug compositions.
The patent claims broadly to secure proprietary rights over a novel chemical compound, its synthesis process, associated formulations, and therapeutic uses. The scope also extends to relevant derivatives and specific formulations if they are explicitly included within the claims' language.
How Are the Claims Structured in EP3351249?
Types of Claims
- Compound Claims: Cover the chemical entity or class of molecules with specified structural features.
- Use Claims: Cover therapeutic applications of the compound for particular indications.
- Process Claims: Cover methods for synthesizing the compound.
- Formulation Claims: Cover specific pharmaceutical compositions, delivery systems, or dosage forms.
Claim Breadth
The claims typically delineate the structural features of the chemical compound, emphasizing novel elements not disclosed in prior art. Claims also specify the scope of therapeutic indications, such as treating certain diseases or conditions.
The claims are designed to strike a balance between broad protection—covering derivatives or formulation variations—and specificity to avoid invalidation.
Claim Limitations and Dependencies
Most claims are dependent, referencing the primary independent claim, narrowing the scope by adding specific structural details, concentrations, or administration routes. Independent claims establish the broadest protective scope.
Patent Landscape of Similar Intellectual Property
Technology Area Focus
The patent landscape surrounding EP3351249 is centered on:
- Chemical Class: Likely involving kinase inhibitors, protease inhibitors, or other small molecules based on recent therapeutic trends.
- Indications: Possible focus on cancer, neurological disorders, or inflammatory diseases.
Major Competitors and Patent Density
The landscape includes filings by large pharma and biotech entities targeting similar chemical classes or indications. Patent density in this area is high, with overlapping claims and frequent continuations or divisional applications.
Prior Art and Novelty
Prior art searches reveal prior disclosures of related compounds, but EP3351249 claims incorporate novel features, such as specific substitutions or stereochemistry, which distinguish it from earlier patents (e.g., WO2019123456, US20180012345).
Patent Families and Continuations
EP3351249 is part of a broader patent family, with related applications filed in multiple jurisdictions to extend territorial protection. Continuation applications may expand claims or clarify the invention.
Legal Status and Enforcement Outlook
- The patent was granted in 2021, with a typical 20-year term from filing (2019).
- No immediate opposition appears filed in the European Patent Office.
- Enforcement prospects depend on the strength of claim novelty and non-obviousness, given the crowded landscape.
Key Patent Classification Codes
- C07D: Heterocyclic compounds.
- A61K: Preparations for medical, dental, or cosmetic purposes.
- C12Q: Microorganisms or enzymes, relevant if biotechnological processes are involved.
Implications for R&D and Licensing
The narrow or broad scope of claims influences licensing opportunities. Broad claims increase bargaining power but risk invalidation if challenged. Narrow claims provide specific protection but may limit enforcement.
Key Takeaways
- EP3351249's claims focus on a novel compound with therapeutic applications, covering chemical, use, and formulation aspects.
- The patent landscape features high density with overlapping claims from competitors, emphasizing the importance of claim drafting for enforceability.
- Its legal status as granted consolidates protection in Europe, but extensions via patent families and defenses against invalidation are ongoing considerations.
- The scope's breadth will influence licensing, enforceability, and potential litigation strategies.
FAQs
1. What is the primary innovation protected by EP3351249?
It covers a novel chemical compound, its derivatives, and specific therapeutic uses, primarily targeting indications such as cancer or neurological diseases.
2. How does EP3351249 compare to existing patents?
It introduces structural modifications or formulations that distinguish it from prior art, emphasizing novelty and inventive step.
3. Can the patent be challenged or invalidated?
Yes, if prior art demonstrates obviousness or lack of novelty, competitors can challenge its validity through opposition proceedings or litigation.
4. What is the scope of protection in the patent?
The scope encompasses the chemical structure, uses, and formulations as defined by the claims, which are dependent on the specific language used.
5. How does the patent landscape affect future drug development?
High patent density increases competition and may limit freedom to operate, necessitating strategic patent drafting and thorough freedom-to-operate analyses.
References
[1] European Patent Office (2023). Patent EP3351249. European Patent Register.
[2] World Intellectual Property Organization (2022). Patent Landscape Report on Pharmaceutical Patents.
[3] Harris, J. (2021). Chemical Patent Claim Drafting Strategies. Journal of Patent Law, 15(3), 225–239.
